V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330005565 | 330002658 | 1.85 | null | Not known (9) | 2013-12-14 | 2013-12-14 | VIDE | 02 | N | 330024054 | RCEOP |
| 330005566 | 330002658 | 1.57 | 57.7 | Curative (C) | 2015-05-18 | 2015-06-14 | AFATINIB | N | Y | 330024054 | IPILIMUMAB |
| 330005567 | 330002659 | 1.68 | 79.1 | Curative (C) | 2017-08-17 | 2017-08-17 | Epirubicin | 2 | N | 330024070 | METHOTREXATE |
| 330005568 | 330002659 | 1.78 | 84.4 | Disease modification (D) | 2017-01-17 | 2017-01-18 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330024070 | MITOTANE |
| 330005569 | 330010048 | 1.55 | 79.05 | null | 2013-08-19 | 2013-08-19 | Sunitinib | 2 | N | 330024081 | MERCAPTOPURINE |
| 330005570 | 330002660 | null | 0 | null | 2013-03-16 | 2013-03-18 | Cetuximab +Cisplatin + FU (Cycle 1) | N | N | 330024087 | CHOP |
| 330005571 | 330002660 | null | 72.3 | Curative (C) | null | 2013-12-07 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 2 | N | 330024087 | ECX |
| 330005572 | 330002660 | 1.56 | 0 | Palliative (P) | 2013-06-26 | 2013-06-29 | VAC | 2 | Y | 330024087 | FLUOROURACIL + MITOMYCIN |
| 330005573 | 330002660 | 1.6 | 85.7 | Palliative (P) | 2015-10-11 | 2015-11-01 | AML 19 TRIAL | N | N | 330024087 | PEMBROLIZUMAB |
| 330005574 | 330002661 | 0 | 76.3 | Curative (C) | 2013-09-08 | 2013-09-14 | CISPLATIN + DOXORUBICIN + METHOTREXATE | 02 | Y | 330024100 | CISPLATIN + DOX + ETOPOSIDE |
| 330005575 | 330002661 | 1.74 | 78 | Palliative (P) | null | 2018-01-08 | FLAG + Idarubicin | N | N | 330024100 | OXALIPLATIN + MDG |
| 330005576 | 330002662 | null | null | Curative (C) | 2016-09-01 | 2016-09-04 | ALL UKALL2011 Ind A Sht Dex (PAsp) | N | N | 330024112 | MITOTANE |
| 330005577 | 330002663 | 1.83 | 99 | Palliative (P) | 2014-10-25 | 2014-10-25 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | null | null | 330024120 | CAPECITABINE + CARBOPLATIN |
| 330005578 | 330002664 | 1.8 | 84.7 | Palliative (P) | 2014-06-24 | 2014-06-24 | CNS Low Grade Glioma Vinblastine | 2 | N | 330024121 | HYDROXYCARBAMIDE |
| 330005579 | 330002664 | null | 54.6 | Curative (C) | 2017-04-12 | 2017-04-12 | Cyclophosphamide + Docetaxel | 2 | N | 330024121 | AML19 TRIAL |
| 330005580 | 330002664 | 1.78 | null | Disease modification (D) | 2016-07-08 | 2016-07-12 | Capecitabine | N | N | 330024121 | CETUXIMAB + CISPLATIN + FU |
| 330005581 | 330002664 | null | 60 | Curative (C) | 2015-12-01 | 2015-12-06 | Folfirinox | N | N | 330024121 | UKALL60+ |
| 330005582 | 330002664 | 1.77 | 87.6 | Disease modification (D) | null | 2014-02-26 | CARBOPLATIN + RT | N | N | 330024121 | UKALL60+ |
| 330005583 | 330012715 | 1.7 | 85.8 | Curative (C) | 2016-09-17 | 2016-09-18 | Bendamustine + prednisolone | 02 | N | 330024126 | RCEOP |
| 330005584 | 330012715 | 1.68 | 64.5 | Curative (C) | null | 2013-08-07 | FCR Oral - Cycle 1 | null | null | 330024126 | VIDE |
| 330005585 | 330002665 | 1.81 | 53 | Neo-adjuvant (N) | 2018-02-05 | 2018-02-05 | RUXOLITINIB | 2 | null | 330024131 | VINBLASTINE |
| 330005586 | 330002665 | 1.75 | 49.4 | Palliative (P) | 2013-10-28 | 2013-11-14 | CARBOPLATIN + RT | N | N | 330024131 | MITOTANE |
| 330005587 | 330010051 | 1.8 | 60.9 | Palliative (P) | 2017-05-18 | 2017-05-30 | RUXOLITINIB | N | N | 330024137 | TRIPLE INTRATHECAL |
| 330005588 | 330002666 | 1.72 | 95 | null | 2013-03-16 | 2013-03-17 | Cisplatin + Pemetrexed | N | N | 330024141 | MITOTANE |
| 330005589 | 330007459 | 1.62 | null | null | 2016-03-29 | 2016-03-29 | Arsenic Triox + Tretinoin Ind W1-4 | 02 | N | 330024144 | ACE (GERM CELL) |
| 330005595 | 330002668 | 1.64 | 73.3 | Palliative (P) | 2015-06-11 | 2015-06-19 | Etoposide + Ifosfamide + HD Mtx | 02 | n | 330024171 | PEMBROLIZUMAB |
| 330005597 | 330002670 | 1.63 | null | Palliative (P) | 2014-01-12 | 2014-01-30 | CNS Low Grade Glioma Vinblastine | 02 | Y | 330024178 | TEMOZOLOMIDE |
| 330005598 | 330002670 | 1.65 | 58 | Curative (C) | 2017-01-17 | 2017-01-17 | ECX | 2 | N | 330024178 | METHOTREXATE INTRATHECAL |
| 330005599 | 330002670 | null | 49 | Curative (C) | 2017-04-20 | 2017-04-20 | VIDE | 02 | N | 330024178 | CISPLATIN + ETOPOSIDE + RT |
| 330005600 | 330011489 | 1.72 | 56.8 | Curative (C) | 2016-12-16 | 2016-12-16 | CAPECITABINE + CARBOPLATIN + Cetuximab | Y | N | 330024185 | BEP |
| 330005601 | 330011489 | null | 76.2 | Palliative (P) | 2017-09-01 | 2017-09-03 | Capecitabine + Lapatinib | N | null | 330024185 | CARBOPLATIN + RT |
| 330005602 | 330011489 | null | null | null | 2015-05-06 | 2015-05-06 | Docetaxel + Gemcitabine (prior RT) | 1 | null | 330024185 | MITOTANE |
| 330005603 | 330011489 | 1.8 | null | Palliative (P) | 2013-05-15 | 2013-05-19 | AML 18 TRIAL | N | null | 330024185 | DOCETAXEL + GEMCITABINE |
| 330005604 | 330011489 | 1.77 | 68.5 | null | 2017-05-03 | 2017-05-08 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330024185 | CVD |
| 330005605 | 330011489 | 1.93 | 85 | Palliative (P) | 2013-11-11 | 2014-02-03 | PEMBROLIZUMAB | N | N | 330024185 | METHOTREXATE |
| 330005606 | 330002671 | 1.7 | 77.3 | Palliative (P) | 2014-12-06 | 2014-12-09 | Carboplatin + Doxorubicin | 02 | N | 330024201 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330005607 | 330002671 | null | 44.1 | null | null | 2014-05-24 | CYCLOPHOSPHAMIDE + FLUDARABINE + RITUXIMAB | null | null | 330024201 | BEP |
| 330005608 | 330002671 | 1.7 | 68.5 | Adjuvant (A) | 2015-11-08 | 2015-11-11 | INTERAACT trial | N | N | 330024201 | BORTEZOMIB |
| 330005609 | 330002671 | 1.58 | 73.5 | Palliative (P) | 2014-06-18 | 2014-07-16 | Cytarabine Low Dose | N | N | 330024201 | CISPLATIN + DOCETAXEL |
| 330005610 | 330002672 | 1.76 | 81 | Curative (C) | 2016-05-04 | 2016-05-05 | CAPECITABINE + LOMUSTINE | N | N | 330024219 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 330005611 | 330002672 | 1.72 | null | Disease modification (D) | 2014-07-25 | 2014-07-25 | Doxorubicin + Ifosfamide | N | N | 330024219 | CAPECITABINE + CARBOPLATIN |
| 330005612 | 330002673 | 1.64 | 60 | Not known (9) | 2017-12-07 | 2017-12-11 | Ipilimumab | N | N | 330024222 | CISPLATIN + DOCETAXEL |
| 330005613 | 330002673 | 1.72 | 78.1 | Palliative (P) | 2017-05-05 | 2017-05-10 | Bortezomib + Cyclophos + Dex | N | N | 330024222 | BENDAMUSTINE |
| 330005614 | 330002673 | 1.65 | 10.4 | Disease modification (D) | 2013-12-29 | 2014-02-09 | GC Int Guide Excranial GermCell JEB | N | N | 330024222 | CISPLATIN + FLUOROURACIL + RT |
| 330005615 | 330011491 | 1.57 | 54.5 | null | 2014-06-10 | 2014-06-10 | GC Int Guide Excranial GermCell JEB | N | N | 330024232 | VINBLASTINE |
| 330005616 | 330002674 | 1.81 | 85.7 | Curative (C) | 2015-03-02 | 2015-03-19 | CYTARABINE | null | null | 330024234 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL |
| 330005617 | 330002675 | null | 77.95 | Disease modification (D) | 2014-11-27 | 2014-11-29 | BORTEZOMIB (twice weekly) | N | null | 330024235 | VIDE |
| 330005618 | 330002675 | 1.67 | 83.2 | Palliative (P) | 2015-09-16 | 2015-09-16 | MITOTANE | 1 | N | 330024235 | DOXORUBICIN + OLARATUMAB |
| 330005619 | 330002676 | 0 | 69 | Disease modification (D) | 2013-06-23 | 2013-07-10 | IMATINIB | 02 | N | 330024241 | CAV |
| 330005620 | 330002677 | 1.69 | 57 | Disease modification (D) | null | 2018-11-10 | Gemcitabine day 1&8 | null | null | 330024245 | FLAG + IDARUBICIN |